Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSForecasting is challenging enough when you have years of historic data to analyze. But what happens when, like biosimilars, your newly launched product is in a new category with little precedent? Or what if your biologic product is facing incoming biosimilar competition? Forecasters launching today are facing exactly this challenge.
As patents on branded biologics expire, the biosimilars industry is expected to take off. But expectations and reality don’t always meet.
The impact of brand loss of exclusivity for patented biologics through 2023 is estimated to be approximately $95 billion, meaning a big hit for current products. The market is also expected to grow quickly – meaning significant opportunity for new entrants. However, IQVIA data shows that biosimilar uptake has not been easy to predict, with many approved products facing delayed launches or slower than expected uptake. Regulations are also still evolving, with most countries establishing their own rules and pace for biosimilar approval and market access.
All of this makes it difficult to accurately predict demand for new biosimilars, or to understand the impact they will have on soon-to-be-patentless biologics.
The lack of historic data, along with trends which haven’t played out as expected, has resulted in inaccurate commercial forecasts. In some cases, biosimilar manufacturers predicted revenues and sales potential multiple times higher than occurred. This led them to invest substantially more resources than was needed on sales teams and production, eroding margins.
No matter how skilled your forecasters are, this level of analysis cannot be completed using spreadsheets and intra-company data. To produce an effective strategy for biosimilars, forecasters must be able to look beyond their internal data and model every player, every product, and every regulatory environment to accurately predict a biosimilar’s current and future potential. That requires a sophisticated forecasting platform that can rapidly access and analyze information, adjust results to accommodate uncertainties, and forecast regional and global trends on a real-time basis.
The technology exists today to achieve these goals. Machine Learning (ML) prediction tools can be connected to global healthcare datasets - and supported by subject matter experts who understand the regional differences in approach to biologics - have produced the most accurate forecasts of biologics uptake to date. But such approaches require forecasters to “step outside” their current ecosystem of spreadsheet-based forecasting and integrate new types of forecasting approaches.
Forecasters looking to accommodate the uncertainties of the biosimilar space should look for platforms or approaches to support them in doing the following:
Biosimilars hold enormous growth potential -- but biopharmaceutical companies need to figure out how to navigate the marketplace and accurately forecast product demand if they are to maximize benefit. Using the right tools and approaches to forecasting biosimilar impact will be critical to achieving early success and gaining (or retaining) market share within this rapidly growing industry sector.
To learn more about our approach to biosimilar forecasting click here or contact us at ForecastHorizon@iqvia.com